Welcome To
Cardiometabolic Health Screening From Future of Medicine
Provide your patients with access to free testing, education, and clinical research opportunities
Promising breakthrough treatments for cardiovascular disease are on the horizon. Create access to leading-edge clinical trials and health screening opportunities for your patients by partnering with Care Access.
Future of Medicine
Help your patients uncover potential health risks and learn about clinical research opportunities that could benefit them, their families and the world.
Free Health Screening
Patients get screened for specific health risks
Health Information
Patients have access to the latest medical information (relevant articles, videos, current research findings) to help them on their health journey
Clinical Trial Opportunities
Patients learn about new clinical trial opportunities based on their health profiles
Become a Trial Access Partner
Cardiometabolic
Health Screening
The medical community is embracing a broader look at heart health that focuses on the shared risks that lead to heart disease as well metabolic and kidney disease. Our no-cost cardiometabolic health screening includes a number of tests, including an Lp(a), which most patients do not currently have access to. In addition to Lp(a), we’ll test for other risk factors of cardiometabolic disease such as Hemoglobin A1C and eGFR.
Importance of Lp(a) Screening for Your Patients
Lipoprotein(a), or Lp(a), has shown to silently block arteries and induce inflammation. Elevated Lp(a) significantly increases the risk of cardiovascular disease, including having a 50% increased risk for a heart attack compared to people with lower Lp(a).1
Elevations in Lp(a) At-a-Glance
Prevalence
Most common genetic dyslipidemia globally, impacting at least 1 in 5 individuals.
Causes
Genetically determined and stable by age 5; not significantly impacted by lifestyle or medications.2
Risks
Lp(a) is associated with a higher risk of heart attack and aortic stenosis. Individuals with Lp(a) levels >30 mg/dL face a high cardiovascular risk, with 1 in 3 individuals falling into this category.3
Clinical Limitations
Lack of targeted therapies has led to limited insurance coverage for testing, which in turn led to a lack of awareness for patients and physicians.
Practice-Changing Breakthroughs on the Horizon
Next generation therapies that use RNA silencing technology to significantly reduce Lp(a) are currently being evaluated in clinical trials.4 These therapies are injections every 1–2 months and can reduce Lp(a) levels by >90%.
1 in 14 heart attacks and
1 in 7 cases of aortic valve disease are due to Lipoprotein(a) cholesterol 5
Screening and Clinical Trials—Offered by You
Community physicians are key to making clinical trials accessible to all patients. By partnering with Care Access as a Trial Access Partner on the Future of Medicine program, you can help your patients get screened for cardiometabolic health risks and access new investigational treatments through your practice.
Here’s how we work with our Trial Access Partners:
Trial Access Partner
Care Access
Learn
You provide patients with information about screening (in-office, EMR messages, phone calls, etc.)
We provide your practice with educational materials and staff support to help spread the word
Schedule
You provide patients with a practice-specific online scheduling link
We handle online scheduling and screening communications
Lab Test
We manage patient screening blood draws at, or near, your office
Results
You receive patients' test results (if they consent) and continue to guide their regular care
We communicate results directly back to patients
Educate
We engage participants with health and clinical research information
Match
You help educate your patients on new trial opportunities
We let participants know if they potentially qualify for a clinical trial. We keep you informed about patients enrolled in trials
Why Become a Partner of the
Future of Medicine Program?
Provide your patients access to free health screening, including testing for Lp(a)
Facilitate patient access to clinical trials for emerging treatments
Help shape the future of medicine
Earn supplemental revenue for your practice
Meet Our Cardiovascular Advisors
The Care Access Cardiovascular Advisory Board provides expert opinion on important issues impacting clinical trials, including patient safety, quality, and creating access for communities that are underrepresented in clinical research. They also provide oversight and guidance for the cardiometabolic health screenings and educational resources provided to those participating in the Future of Medicine program by Care Access.
About Care Access
Care Access is a global research company helping to accelerate the arrival of new medicines. With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies. Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation.
REFERENCES
- Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, Khera AV., Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):465-474. doi: 10.1161/ATVBAHA.120.315291. Epub 2020 Oct 29. PMID: 33115266; PMCID: PMC7769893.
- Reyes-Soffer G., Ginsberg H.N., Berglund L., Duell P.B., Heffron S.P., Kamstrup P.R., Lloyd-Jones D.M., Marcovina S.M., Yeang C., Koschinsky M.L., Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 2022;42:48–60. doi: 10.1161/ATV.0000000000000147
- Rikhi R., Hammoud A., Ashburn N., Snavely A.C., Michos E.D., Chevli P., Tsai M.Y., Herrington D., Shapiro M.D., Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA) Atherosclerosis. 2022;363:102–108. doi: 10.1016 jatherosclerosis.2022.10.004.
- Sosnowska B, Surma S, Banach M., Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy. Pharmaceuticals (Basel). 2022 Dec 16;15(12):1573. doi: 10.3390/ph15121573. PMID: 36559024; PMCID: PMC9781646.
- Afshar M, Kamstrup PR, Williams K, Sniderman AD, Nordestgaard BG, Thanassoulis G., Estimating the population impact of Lp(a) lowering on the incidence of myocardial infarction and aortic stenosis-brief report. Arterioscler Thromb Vasc Biol 2016; 36: 2421–2423.